Koh, S., Wallez, Y., Dunlop, C. R., de Quirós Fernández, S. B., Bapiro, T. E., Richards, F. M., & Jodrell, D. I. (2018). Mechanistic distinctions between CHK1 and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine. Cancer Res.

Koh, Siang-Boon, Yann Wallez, Charles R. Dunlop, Sandra Bernaldo de Quirós Fernández, Tashinga E. Bapiro, Frances M. Richards, et Duncan I. Jodrell. "Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy With Gemcitabine." Cancer Res 2018.

Koh, Siang-Boon, et al. "Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy With Gemcitabine." Cancer Res 2018.